Biltmore Family Office LLC Acquires 288 Shares of Eli Lilly and Company (NYSE:LLY)

Biltmore Family Office LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 9.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,293 shares of the company’s stock after acquiring an additional 288 shares during the period. Biltmore Family Office LLC’s holdings in Eli Lilly and Company were worth $2,917,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Planning Alternatives Ltd. ADV boosted its stake in Eli Lilly and Company by 2.9% in the 3rd quarter. Planning Alternatives Ltd. ADV now owns 559 shares of the company’s stock worth $495,000 after purchasing an additional 16 shares during the period. Raymond James Trust N.A. lifted its holdings in shares of Eli Lilly and Company by 0.7% in the third quarter. Raymond James Trust N.A. now owns 34,943 shares of the company’s stock worth $30,957,000 after buying an additional 240 shares in the last quarter. Valence8 US LP bought a new position in shares of Eli Lilly and Company during the third quarter worth $561,000. Darden Wealth Group Inc grew its stake in Eli Lilly and Company by 3.8% during the third quarter. Darden Wealth Group Inc now owns 1,515 shares of the company’s stock valued at $1,342,000 after acquiring an additional 55 shares in the last quarter. Finally, Eagle Asset Management Inc. increased its holdings in Eli Lilly and Company by 33.8% in the 3rd quarter. Eagle Asset Management Inc. now owns 29,394 shares of the company’s stock valued at $24,443,000 after acquiring an additional 7,425 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

LLY has been the subject of several research reports. Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Barclays dropped their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Bank of America cut their target price on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Finally, Wolfe Research started coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,007.94.

Eli Lilly and Company Stock Down 0.6 %

NYSE:LLY opened at $748.91 on Friday. The company has a market cap of $710.96 billion, a price-to-earnings ratio of 80.96, a price-to-earnings-growth ratio of 2.76 and a beta of 0.43. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The stock has a fifty day simple moving average of $868.53 and a 200-day simple moving average of $869.14.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company’s quarterly revenue was up 20.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.10 EPS. Analysts anticipate that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.69%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.